Animal Pharm is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Joseph Harvey

London
As Editor of Animal Pharm, Joseph Harvey provides news and analysis about the global animal health market across a range of species and products. He conducts exclusive interviews with the sector's biggest companies and experts, as well as start-up firms. He also hosts webinars and gives speeches on the industry.

Having gained many years' experience in business journalism, Joseph joined Informa in 2007, reporting on the medical technology space. He joined Animal Pharm, rising to become editor and taking the publication online only.

Joseph also launched a series of well-received webinars. As author of a top-selling industry report, he detailed the leading companies in the animal health sector. Since becoming editor, he has transformed Animal Pharm from just a news provider into a more in-depth analytical service.
Advertisement
Set Alert for Articles By Joseph Harvey

Latest From Joseph Harvey

Dechra makes a small but significant acquisition in New Zealand

Dechra Pharmaceuticals has again returned to Australasia for its latest acquisition. 

New Zealand Companion Animals

Jaguar taps the Middle East equine market with key deal in Dubai

Jaguar Health has opened up a range of commercial possibilities in the Middle East by securing a collaborative partnership with a notable Dubai-based firm.

Middle East and Africa United Arab Emirates

Kane Biotech sets its sights on European market entry

Canadian business Kane Biotech wants to take its companion animal oral care products to the European sector. 

Europe North America

Elanco's potential exit from Lilly could deprive animal health of more R&D funds

One possible path for Elanco next year could see it become a standalone entity. While this option will have some benefits for Elanco, it would see the firm lose the R&D capabilities its parent company has to offer. Animal Pharm editor Joseph Harvey takes a closer look at the potential situation. 

R&D Investments

KindredBio pivotal results bring Zimeta closer to approval

Kindred Biosciences has moved a step closer to US authorization of Zimeta (dipyrone oral gel) for the control of pyrexia in horses. 

Kindred Biosciences Pharmaceuticals

Boehringer backs vaccines with $80m expansion in Georgia and Missouri

Boehringer Ingelheim Vetmedica (BIVI) is pre-empting an increased demand for veterinary vaccines by spending $80 million on expanding its existing facilities in Athens, Georgia and St Joseph, Missouri. 

Boehringer Ingelheim Animal Health Operations
See All
Advertisement
UsernamePublicRestriction

Register